Targeting Immune Checkpoints as Cancer Therapy

In recent years, the field of oncology has witnessed a paradigm shift with the advent of immunotherapy, a treatment modality that harnesses the body's immune system to combat cancer. Among the most promising approaches in immunotherapy is the targeting of immune checkpoints. These molecular pathways are crucial for maintaining self-tolerance and modulating the immune response to prevent autoimmunity. However, cancer cells cleverly exploit these pathways to evade immune detection and destruction. This article delves into the mechanisms of immune checkpoint pathways, their role in cancer evasion, and the therapeutic strategies designed to inhibit these checkpoints, thereby reactivating the immune system against cancer cells.

Understanding Immune Checkpoints:

Immune checkpoints refer to a collection of inhibitory pathways in the immune system that are critical for maintaining immune homeostasis and preventing the immune system from attacking the body's own cells. The most studied checkpoints include the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed death-1 (PD-1) pathway, along with its ligand PD-L1. These checkpoints act as "brakes" on the immune system, ensuring that immune responses are modulated and do not result in autoimmunity.

  • The CTLA-4 Checkpoint

CTLA-4 is a molecule found on the surface of T cells, where it primarily regulates the amplitude of the early stages of T cell activation. By outcompeting the stimulatory receptor CD28 for binding to B7 molecules on antigen-presenting cells (APCs), CTLA-4 inhibits T cell activation, serving as a critical checkpoint for immune regulation.

  • The PD-1/PD-L1 Checkpoint

The PD-1 receptor is another inhibitory checkpoint expressed on T cells and other immune cells. Its interaction with PD-L1, expressed on tumor cells and some immune cells, leads to the inhibition of T cell proliferation, cytokine production, and cytotoxic activity. This pathway plays a significant role in the ability of tumor cells to evade immune surveillance by effectively "turning off" T cells that could potentially recognize and destroy cancer cells.

Targeting Checkpoints in Cancer Therapy:

The discovery of immune checkpoints and their role in immune evasion has led to the development of checkpoint inhibitors, a class of drugs that block these inhibitory pathways, thereby reactivating the immune system against cancer. The therapeutic blockade of CTLA-4, PD-1, and PD-L1 has shown remarkable efficacy in various cancers, leading to durable responses and, in some cases, long-term remission.

  • CTLA-4 Inhibitors

The first CTLA-4 inhibitor, ipilimumab, was approved by the FDA for the treatment of metastatic melanoma. By blocking CTLA-4, ipilimumab enhances T cell activation and proliferation, leading to an augmented immune response against melanoma cells. Clinical trials have demonstrated a significant improvement in survival among patients treated with ipilimumab, establishing the role of CTLA-4 blockade in cancer therapy.

  • PD-1 and PD-L1 Inhibitors

Following the success of CTLA-4 inhibitors, drugs targeting the PD-1/PD-L1 pathway were developed and approved for the treatment of various cancers, including non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and Hodgkin lymphoma. Nivolumab and pembrolizumab, two anti-PD-1 antibodies, have been shown to reactivate T cell responses and achieve significant tumor regression in several cancer types. Similarly, PD-L1 inhibitors such as atezolizumab have been effective in cancers with high PD-L1 expression, offering a new therapeutic option for patients with difficult-to-treat cancers.

Targeting Immune checkpoints inhibitors in cancer therapy

Figure: Immune Checkpoint Inhibitors in Cancer Therapy

Challenges and Future Directions:

While immune checkpoint inhibitors have revolutionized cancer therapy, not all patients respond to these treatments, and some develop resistance. The reasons for this variability are complex and include factors such as tumor heterogeneity, the tumor microenvironment, and differences in individual immune systems. Ongoing research is focused on understanding these mechanisms of resistance and developing combination therapies that might overcome them. Strategies include combining checkpoint inhibitors with other forms of immunotherapy, targeted therapies, or traditional chemotherapy to enhance anti-tumor responses.

Additionally, the identification of novel immune checkpoints and their inhibitors continues to be an area of intense research. New targets such as LAG-3, TIM-3, and TIGIT are being explored, with the potential to offer new avenues for cancer treatment.


The targeting of immune checkpoints has opened new horizons in cancer therapy, offering hope to many patients with previously untreatable cancers. The success of CTLA-4, PD-1, and PD-L1 inhibitors underscores the importance of the immune system in controlling cancer and highlights the potential of immunotherapy as a cornerstone of cancer treatment. As research progresses, the future of cancer therapy looks increasingly promising, with the potential for more personalized and effective treatment strategies that harness the power of the immune system to combat cancer.


  1. Pardoll, D.M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 12(4), 252-264.
  2. Postow, M.A., Callahan, M.K., & Wolchok, J.D. (2015). Immune Checkpoint Blockade in Cancer Therapy. Journal of Clinical Oncology, 33(17), 1974-1982.
  3. Ribas, A., & Wolchok, J.D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350-1355.
  4. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., ... & Robert, C. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711-723.
  5. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., ... & Sznol, M. (2012). Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. New England Journal of Medicine, 366(26), 2443-2454.
  6. Sharma, P., & Allison, J.P. (2015). The future of immune checkpoint therapy. Science, 348(6230), 56-61.
  7. Weber, J.S., D'Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., ... & Ascierto, P.A. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology, 16(4), 375-384.
  8. Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., ... & Waterkamp, D. (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. The Lancet, 387(10030), 1837-1846.

Written by Tehreem Ali

Tehreem Ali completed her MS in Bioinformatics and conducted her research work at the IOMM lab at GCUF, Pakistan.

16th Feb 2024 Tehreem Ali

Recent Posts